{"entity":{"id":"nct06166589","kind":"trial","name":"Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of zimberelimab, cAPOX (capecitabine, oxaliplatin), tegafur, gimeracil and oteracil (S-1) and fOLFIRI (5-FU, leucovorin, irinotecan) in pancreatic cancer, run by Shanghai Zhongshan Hospital, not yet recruiting.","summary":"Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer is a phase 2, interventional study registered as NCT06166589 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 19 participants, started 2024-01-01 and due to reach its primary completion in 2026-01-01. Interventions recorded: Zimberelimab; Oxaliplatin; S-1; Irinotecan. Conditions listed: Previously AG Chemotherapy Treated Pancreatic Cancer. Primary outcome: ORR. Pancreatic eligibility wording from the registry: \"* Patients with pancreatic cancer progressing after first-line AG regimen chemotherapy, including patients with advanced pancreatic cancer progressing after first-line AG regimen chemotherapy and patients with recurrence and metastasis after radical pancreatic cancer surgery assisted by AG regimen c\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06166589","url":"https://clinicaltrials.gov/study/NCT06166589"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["zimberelimab","capox","tegafur-gimeracil-oteracil","folfiri"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06166589","phase":"2","setting":"The Efficacy and Safety of Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer: A Prospective, Single Arm, Phase II Clinical Study","sponsor":"Shanghai Zhongshan Hospital","enrolled":19,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06166589/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"tegafur-gimeracil-oteracil","kind":"drug","name":"Tegafur, gimeracil and oteracil (S-1)","route":"/drugs/tegafur-gimeracil-oteracil/"},{"id":"zimberelimab","kind":"drug","name":"Zimberelimab","route":"/drugs/zimberelimab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}